Female Infertility Market Report 2026

The female infertility market size has grown steadily in recent years. It will grow from $1.86 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to delayed childbearing trends, increased awareness of infertility, availability of fertility drugs, expansion of reproductive health clinics, improved diagnostic imaging.

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to advancements in fertility drug formulations, growth in personalized fertility treatments, increased adoption of AI-based fertility tracking, expansion of fertility tourism, rising investment in reproductive health. Major trends in the forecast period include rising demand for assisted reproductive treatments, increased focus on hormonal and ovulation therapies, growing use of advanced diagnostic techniques, expansion of fertility clinics and services, integration of digital platforms in fertility care.

The rising prevalence of infertility is expected to drive growth in the female infertility market in the coming years. Infertility is defined as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The increase in infertility is influenced by factors such as delayed childbearing, lifestyle changes, environmental toxins, rising obesity, and higher stress levels. Female infertility treatments are necessary to address and manage underlying medical, hormonal, or structural issues that affect fertility, thereby improving the chances of conception and preventing permanent infertility. For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 17.5% of the global adult population, or about 1 in 6 individuals, experience infertility. Therefore, the growing prevalence of infertility is fueling the expansion of the female infertility market.

Key companies in the female infertility market are focusing on developing innovative solutions, such as non-invasive diagnostic tests, to gain a competitive advantage. A non-invasive diagnostic test is a medical procedure that identifies conditions or diseases without requiring surgery or penetration of the body. For instance, in August 2024, Heranova Lifesciences, a US-based biotech company, launched an early access program for HerResolve, a non-invasive diagnostic test for endometriosis. Endometriosis affects around 200 million women worldwide, causing symptoms such as infertility, pain, and abnormal bleeding. For many women, obtaining an accurate diagnosis can take an average of 7-10 years from the onset of symptoms, primarily due to varied symptom presentation and the invasive nature of the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve has the potential to reduce this diagnostic delay from years to months, improving patient care and healthcare outcomes.

In April 2023, CCRM Fertility, a US-based fertility clinic network, acquired the New Hope Center for Reproductive Medicine for an undisclosed sum. This acquisition expands CCRM’s presence on the East Coast, providing easier access to advanced fertility care, comprehensive testing, state-of-the-art laboratories, and in-house genetics and research, ensuring leading success rates. The New Hope Center for Reproductive Medicine is a US-based fertility clinic offering a range of services, including in vitro fertilization (IVF), to address female infertility.

Major companies operating in the female infertility market are Pfizer Inc, Merck And Co Inc, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Organon Theramex, Juniper Reproductive Health Ltd, Ferring Pharmaceuticals, Mankind Pharma, ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Merck KGaA, Gedeon Richter Plc, Novartis AG, AbbVie Inc, Ipsen, Theramex, Vitrolife AB, Conceivable Life Sciences, AIVF.

Europe was the largest region in the female infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the female infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the female infertility market by increasing costs for imported fertility drugs, hormonal injections, and pharmaceutical ingredients. Hospital and retail pharmacies in Asia-Pacific and developing regions are most affected due to reliance on global fertility drug suppliers. These higher costs can reduce patient access to infertility treatments. However, tariffs are encouraging domestic drug manufacturing and formulation, improving long-term affordability.

The female infertility market research report is one of a series of new reports that provides female infertility market statistics, including female infertility industry global market size, regional shares, competitors with a female infertility market share, detailed female infertility market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. This female infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older), or the inability to carry a pregnancy to term. It is a complex condition caused by various factors that affect the reproductive system.

The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is a medication commonly used to stimulate ovulation in women experiencing infertility. It can be administered via multiple routes, including oral and parenteral, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.